ClinicalTrials.Veeva

Menu

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Cystic Fibrosis

Treatments

Drug: TEZ/IVA
Drug: Placebo (matched to VX-659/TEZ/IVA)
Drug: VX-659
Drug: TEZ
Drug: VX-561
Drug: IVA
Drug: Placebo (matched to VX-659/TEZ/VX-561)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03224351
2016-003585-11 (EudraCT Number)
VX16-659-101

Details and patient eligibility

About

This is a Phase 2, randomized, double-blind, placebo- and tezacaftor/ivacaftor (TEZ/IVA)-controlled, parallel-group, 3-part, multicenter study designed to evaluate the safety and efficacy of VX-659 in triple combination (TC) with TEZ and IVA in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or TEZ/IVA (F/MF genotypes).

Enrollment

124 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Body weight ≥35 kg.

  • Subjects must have an eligibleCFTR genotype.

    • Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)
    • Part 2: Homozygous for F508del (F/F)
  • FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

Key Exclusion Criteria:

  • History of clinically significant cirrhosis with or without portal hypertension.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Lung infection with organisms associated with a more rapid decline in pulmonary status.
  • History of solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

124 participants in 8 patient groups, including a placebo group

Part 1: Placebo
Placebo Comparator group
Description:
Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
Treatment:
Drug: Placebo (matched to VX-659/TEZ/IVA)
Part 1: VX-659/TEZ/IVA TC - Low Dose
Experimental group
Description:
Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Treatment:
Drug: IVA
Drug: VX-659
Drug: TEZ/IVA
Part 1: VX-659/TEZ/IVA TC - Medium Dose
Experimental group
Description:
Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Treatment:
Drug: IVA
Drug: VX-659
Drug: TEZ/IVA
Part 1: VX-659/TEZ/IVA TC - High Dose
Experimental group
Description:
Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
Treatment:
Drug: IVA
Drug: VX-659
Drug: TEZ/IVA
Part 2: TEZ/IVA
Active Comparator group
Description:
Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
Treatment:
Drug: IVA
Drug: TEZ/IVA
Part 2: VX-659/TEZ/IVA TC
Experimental group
Description:
Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
Treatment:
Drug: IVA
Drug: VX-659
Drug: TEZ/IVA
Part 3: Placebo
Placebo Comparator group
Description:
Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
Treatment:
Drug: Placebo (matched to VX-659/TEZ/VX-561)
Part 3: VX-659/TEZ/VX-561 TC
Experimental group
Description:
Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
Treatment:
Drug: VX-659
Drug: VX-561
Drug: TEZ

Trial documents
2

Trial contacts and locations

47

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems